proxyvotesnow.com

Home › Companies › ZEVRA THERAPEUTICS INC. › 2023-2024

ZEVRA THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and ZEVRA THERAPEUTICS INC.’s Form 8-K, filed 2024-05-13 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 6Reported items
  • 106Asset managers
  • 616Fund votes
  • 2024-05-13Meeting date

Proxy season: 2023-2024

Explore ZEVRA THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by ZEVRA THERAPEUTICS INC.

These tallies are ZEVRA THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-05-13 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ZEVRA THERAPEUTICS INC. — official shareholder meeting results, meeting held 2024-05-13
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Of the 41,850,494 shares outstanding as of the March 22, 2024 record date, at least 31,194,215 shares, or 74.54%, were present or represented by proxy at the 2024 Annual Meeting. At the 2024 Annual Meeting, each of Thomas D. 15,266,761---- 6,062,2689,865,186 Majority: yes
Elect Director: Approval, on an advisory and non-binding basis, of the compensation of the Company's named executive officers. 11,167,2159,888,153273,661 --9,865,186 Majority: yes

Source: ZEVRA THERAPEUTICS INC., Form 8-K, filed with the SEC on 2024-05-13 — read the filing on EDGAR.

How asset managers voted at the ZEVRA THERAPEUTICS INC. 2023-2024 meeting

Each item below shows how the 106 asset managers that disclosed a ZEVRA THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ZEVRA THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy materials

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

53.0% Majority: yes · of votes cast

FOR 53.0%AGAINST 47.0%
FOR: 11,167,215AGAINST: 9,888,153

ZEVRA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Approval, on an advisory and non-binding basis, of the compensation of the Company's named executive officers.”): 11,167,215 for, 9,888,153 against, per its Form 8-K filed 2024-05-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 41,853,494 outstanding shares: 27% for, 24% against (50.3% of the company cast a for/against vote).

The 104 asset managers below cast 98% of the shares they voted on this item FOR (8,898,628 for, 172,457 against).

FOR 98%
FOR: 8,898,628 (98.1%)AGAINST: 172,457 (1.9%)
Largest asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in t” at ZEVRA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard1,526,6180 00For
BlackRock1,387,1160 00For
Woodline Partners LP841,8230 00For
683 Capital Management, LLC779,1790 00For
Janney Montgomery Scott LLC674,2310 00For
State Street672,3030 00For
GEODE CAPITAL MANAGEMENT, LLC442,9520 00For
PNC BANK, NATIONAL ASSOCIATION428,2100 00For
Fidelity400,9350 00For
Altium Capital Management LP280,2810 00For
Northern Trust173,32819 00For
Wellington107,2290 00For
Nuveen103,9410 00For
TIAA103,9410 00For
Newton Investment Management North America, LLC099,515 00Against
Point7292,6020 00For
Charles Schwab89,0680 00For
MELLON INVESTMENTS Corp65,3880 00For
BRIDGEWAY CAPITAL MANAGEMENT, LLC64,5250 00For
Nantahala Capital Management, LLC62,2290 00For
BRIDGEWAY FUNDS INC58,8250 00For
QUANTITATIVE MASTER SERIES LLC53,9250 00For
Renaissance46,4040 00For
American Century036,366 00Against
John Hancock32,2420 00For

Showing the 25 largest of 104 asset managers. See all 104 in the interactive database.

2. Election of Directors: Alvin Shih, M.D.

DIRECTOR ELECTIONS

Combines 3 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 34 asset managers below cast 100% of the shares they voted on this item FOR (3,489,280 for, 0 against).

FOR: 3,489,280 (100.0%)
Largest asset managers voting on “Election of Directors: Alvin Shih, M.D.” at ZEVRA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard1,506,9180 00For
BlackRock787,2450 00For
Fidelity400,3800 00For
Altium Capital Management LP280,2810 00For
TIAA103,9410 00For
BRIDGEWAY FUNDS INC58,8250 00For
QUANTITATIVE MASTER SERIES LLC53,9250 00For
Charles Schwab44,5340 00For
Lincoln Financial29,4000 00For
Dimensional24,5050 00For
Global X19,0720 00For
American Century18,1830 00For
AIG/SunAmerica17,7230 00For
John Hancock16,1210 00For
Northern Trust15,7320 00For
State Street14,1690 00For
Pacific Life13,7440 00For
Bridge Builder Trust13,4590 00For
Voya12,8730 00For
Columbia Threadneedle12,5100 00For
Equitable9,7620 00For
Nationwide5,6170 00For
DWS5,3190 00For
Victory Capital5,0240 00For
Principal4,2330 00For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

3. Election of Directors: Neil F. McFarlane

DIRECTOR ELECTIONS

Combines 3 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 34 asset managers below cast 100% of the shares they voted on this item FOR (3,489,280 for, 0 against).

FOR: 3,489,280 (100.0%)
Largest asset managers voting on “Election of Directors: Neil F. McFarlane” at ZEVRA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard1,506,9180 00For
BlackRock787,2450 00For
Fidelity400,3800 00For
Altium Capital Management LP280,2810 00For
TIAA103,9410 00For
BRIDGEWAY FUNDS INC58,8250 00For
QUANTITATIVE MASTER SERIES LLC53,9250 00For
Charles Schwab44,5340 00For
Lincoln Financial29,4000 00For
Dimensional24,5050 00For
Global X19,0720 00For
American Century18,1830 00For
AIG/SunAmerica17,7230 00For
John Hancock16,1210 00For
Northern Trust15,7320 00For
State Street14,1690 00For
Pacific Life13,7440 00For
Bridge Builder Trust13,4590 00For
Voya12,8730 00For
Columbia Threadneedle12,5100 00For
Equitable9,7620 00For
Nationwide5,6170 00For
DWS5,3190 00For
Victory Capital5,0240 00For
Principal4,2330 00For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

4. Election of Directors: Thomas D. Anderson

DIRECTOR ELECTIONS

Combines 3 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 34 asset managers below cast 100% of the shares they voted on this item FOR (3,489,280 for, 0 against).

FOR: 3,489,280 (100.0%)
Largest asset managers voting on “Election of Directors: Thomas D. Anderson” at ZEVRA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard1,506,9180 00For
BlackRock787,2450 00For
Fidelity400,3800 00For
Altium Capital Management LP280,2810 00For
TIAA103,9410 00For
BRIDGEWAY FUNDS INC58,8250 00For
QUANTITATIVE MASTER SERIES LLC53,9250 00For
Charles Schwab44,5340 00For
Lincoln Financial29,4000 00For
Dimensional24,5050 00For
Global X19,0720 00For
American Century18,1830 00For
AIG/SunAmerica17,7230 00For
John Hancock16,1210 00For
Northern Trust15,7320 00For
State Street14,1690 00For
Pacific Life13,7440 00For
Bridge Builder Trust13,4590 00For
Voya12,8730 00For
Columbia Threadneedle12,5100 00For
Equitable9,7620 00For
Nationwide5,6170 00For
DWS5,3190 00For
Victory Capital5,0240 00For
Principal4,2330 00For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

5. To approve amendments to the Company's Amended and Restated 2014 Equity Incentive Plan

COMPENSATION

Combines 2 wordings of this item as funds reported it.

8% fund support · no official result

8%AGAINST 92%

The 34 asset managers below cast 8% of the shares they voted on this item FOR (280,281 for, 3,208,999 against).

FOR: 280,281 (8.0%)AGAINST: 3,208,999 (92.0%)
Largest asset managers voting on “To approve amendments to the Company's Amended and Restated 2014 Equity Incentive Plan” at ZEVRA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard01,506,918 00Against
BlackRock0787,245 00Against
Fidelity0400,380 00Against
Altium Capital Management LP280,2810 00For
TIAA0103,941 00Against
BRIDGEWAY FUNDS INC058,825 00Against
QUANTITATIVE MASTER SERIES LLC053,925 00Against
Charles Schwab044,534 00Against
Lincoln Financial029,400 00Against
Dimensional024,505 00Against
Global X019,072 00Against
American Century018,183 00Against
AIG/SunAmerica017,723 00Against
John Hancock016,121 00Against
Northern Trust015,732 00Against
State Street014,169 00Against
Pacific Life013,744 00Against
Bridge Builder Trust013,459 00Against
Voya012,873 00Against
Columbia Threadneedle012,510 00Against
Equitable09,762 00Against
Nationwide05,617 00Against
DWS05,319 00Against
Victory Capital05,024 00Against
Principal04,233 00Against

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

6. To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024

AUDIT-RELATED

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 34 asset managers below cast 100% of the shares they voted on this item FOR (3,489,280 for, 0 against).

FOR: 3,489,280 (100.0%)
Largest asset managers voting on “To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Com” at ZEVRA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard1,506,9180 00For
BlackRock787,2450 00For
Fidelity400,3800 00For
Altium Capital Management LP280,2810 00For
TIAA103,9410 00For
BRIDGEWAY FUNDS INC58,8250 00For
QUANTITATIVE MASTER SERIES LLC53,9250 00For
Charles Schwab44,5340 00For
Lincoln Financial29,4000 00For
Dimensional24,5050 00For
Global X19,0720 00For
American Century18,1830 00For
AIG/SunAmerica17,7230 00For
John Hancock16,1210 00For
Northern Trust15,7320 00For
State Street14,1690 00For
Pacific Life13,7440 00For
Bridge Builder Trust13,4590 00For
Voya12,8730 00For
Columbia Threadneedle12,5100 00For
Equitable9,7620 00For
Nationwide5,6170 00For
DWS5,3190 00For
Victory Capital5,0240 00For
Principal4,2330 00For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

Largest ZEVRA THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked by the number of ZEVRA THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 41,853,494 shares outstanding at the time of that meeting.

Top ZEVRA THERAPEUTICS INC. shareholders by shares voted, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 3.65%
2BlackRock 3.31%
3Woodline Partners LP 2.01%
4683 Capital Management, LLC 1.86%
5Janney Montgomery Scott LLC 1.61%
6State Street 1.61%
7GEODE CAPITAL MANAGEMENT, LLC 1.06%
8PNC BANK, NATIONAL ASSOCIATION 1.02%
9Fidelity 0.96%
10Altium Capital Management LP 0.67%

Reported ZEVRA THERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

ZEVRA THERAPEUTICS INC. beneficial owners on record for the 2023-2024 proxy season
Holder % outstanding Disclosure
BlackRock 9.65% 13F
Vanguard Group 7.37% 13F
Nantahala Capital Management, LLC 5.86% DEF14A
FMR (Fidelity) 3.91% 13F
Travis Mickle, Ph.D. 1.95% DEF14A
Geode Capital 1.88% 13F
Goldman Sachs 1.82% 13F
State Street 1.63% 13F
Morgan Stanley 1.33% 13F
JPMorgan Chase 1.05% 13F

Percentages above are of 41,853,494 shares outstanding, as reported by ZEVRA THERAPEUTICS INC. on its Form 10-Q dated 2024-05-03 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ZEVRA THERAPEUTICS INC.’s 10-Q dated 2024-05-03. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At ZEVRA THERAPEUTICS INC.'s shareholder meeting held 2024-05-13, in the 2023-2024 proxy season, 106 asset managers reported how they voted in their SEC Form N-PX filings, covering 616 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers as… — FOR was 53.0% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: ZEVRA THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-05-13.

ZEVRA THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page).